Overexpression of metabolic markers PKM2 and LDH5 correlates with aggressive clinicopathological features and adverse patient prognosis in tongue cancer
Chunping Yuan
Oral Cancer Center, Institute of Stomatology, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
These authors contributed equally to this work.Search for more papers by this authorZhongwu Li
Oral Cancer Center, Institute of Stomatology, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
These authors contributed equally to this work.Search for more papers by this authorYanling Wang
Oral Cancer Center, Institute of Stomatology, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorBin Qi
Department of Oral Pathology, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorWei Zhang
Department of Oral Pathology, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorJinhai Ye
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorHeming Wu
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorHongbin Jiang
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorLiang-Nian Song
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
Search for more papers by this authorJianrong Yang
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorCorresponding Author
Jie Cheng
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Address for correspondence: Jie Cheng, PhD, DDS, Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, 136, Hanzhong Road, Nanjing 210029, China PRC. e-mail: [email protected]Search for more papers by this authorChunping Yuan
Oral Cancer Center, Institute of Stomatology, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
These authors contributed equally to this work.Search for more papers by this authorZhongwu Li
Oral Cancer Center, Institute of Stomatology, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
These authors contributed equally to this work.Search for more papers by this authorYanling Wang
Oral Cancer Center, Institute of Stomatology, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorBin Qi
Department of Oral Pathology, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorWei Zhang
Department of Oral Pathology, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorJinhai Ye
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorHeming Wu
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorHongbin Jiang
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorLiang-Nian Song
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
Search for more papers by this authorJianrong Yang
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Search for more papers by this authorCorresponding Author
Jie Cheng
Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, Jiangsu, China
Address for correspondence: Jie Cheng, PhD, DDS, Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, 136, Hanzhong Road, Nanjing 210029, China PRC. e-mail: [email protected]Search for more papers by this authorAbstract
Aims
Pyruvate kinase M2 (PKM2) and lactate dehydrogenase 5 (LDH5) are two metabolic and oncogenic markers of cancer. In this study, we sought to investigate their expression patterns and prognostic value in tongue squamous cell carcinoma (TSCC).
Methods and results
The expression and subcellular localization of PKM2 and LDH5 in TSCC cell lines were determined by Western blot and immunofluorescence. PKM2 and LDH5 abundance was examined by immunohistochemistry in 63 TSCC tumour specimens; their association with multiple clinicopathological parameters and overall patient survival was assessed. The protein levels of PKM2 and LDH5 were both significantly higher in TSCC cells than in an immortalized oral epithelial cell line. Overexpression of PKM2 associated significantly with cervical node metastasis (P = 0.0373), while elevated LDH5 levels correlated significantly with tumour size (P = 0.0094), pathological grade (P = 0.0052), cervical node metastasis (P = 0.0023) and clinical stage (P = 0.0024). Patients with tumours showing an increase in either PKM2 or LDH5 expression displayed significantly reduced overall survival, while patients with tumours overexpressing both proteins showed the worst prognosis with lowest overall survival. Furthermore, PKM2 and LDH5 were identified as independent prognostic predictors for overall patient survival in TSCC.
Conclusion
Our data indicate that overexpression of PKM2 and LDH5 associates with key clinicopathological features and unfavourable prognosis in TSCC.
References
- 1Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371; 1695–1709.
- 2Scully C, Bagan JV. Recent advances in oral oncology 2008; squamous cell carcinoma imaging, treatment, prognostication and treatment outcomes. Oral Oncol. 2009; 45; e25–e30.
- 3Rapidis AD, Gullane P, Langdon JD, Lefebvre JL, Scully C, Shah JP. Major advances in the knowledge and understanding of the epidemiology, aetiopathogenesis, diagnosis, management and prognosis of oral cancer. Oral Oncol. 2009; 45; 299–300.
- 4Bello IO, Soini Y, Salo T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II). Oral Oncol. 2010; 46; 636–643.
- 5Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144; 646–674.
- 6Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012; 21; 297–308.
- 7Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011; 11; 85–95.
- 8Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134; 703–707.
- 9Chaneton B, Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem. Sci. 2012; 37; 309–316.
- 10Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. Clin. Cancer Res. 2012; 18; 5554–5561.
- 11Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 2013; 123; 3685–3692.
- 12Peng XC, Gong FM, Zhao YW et al. Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma. PLoS One 2011; 6; e27309.
- 13Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004; 84; 1014–1020.
- 14Kolev Y, Uetake H, Takagi Y, Sugihara K. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann. Surg. Oncol. 2008; 15; 2336–2344.
- 15Yin L, Wang X, Luo C et al. The value of expression of M2-PK and VEGF in patients with advanced gastric cancer. Cell Biochem. Biophys. 2013; 67; 1033–1039.
- 16Sun Q, Chen X, Ma J et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl Acad. Sci. USA 2011; 108; 4129–4134.
- 17Luo W, Hu H, Chang R et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011; 145; 732–744.
- 18Yang W, Xia Y, Hawke D et al. PKM2 phosphorylates histone h3 and promotes gene transcription and tumorigenesis. Cell 2012; 150; 685–696.
- 19Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25; 4633–4646.
- 20Le A, Cooper CR, Gouw AM et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl Acad. Sci. USA 2010; 107; 2037–2042.
- 21Parnell KM, Foulks JM, Nix RN et al. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol. Cancer Ther. 2013; 12; 1453–1460.
- 22Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9; 425–434.
- 23Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, Wai-Man Ng R, Ignace Wei W. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int. J. Cancer 2008; 23; 251–257.
- 24Grimm M, Alexander D, Munz A, Hoffmann J, Reinert S. Increased LDH5 expression is associated with lymph node metastasis and outcome in oral squamous cell carcinoma. Clin. Exp. Metastasis 2013; 30; 529–540.
- 25Feng C, Gao Y, Wang C et al. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2013; 98; E1524–E1533.
- 26Zhong LP, Pan HY, Zhou XJ et al. Characteristics of a cancerous cell line, HIOEC-b(a)p-96, induced by benzo(a)pyrene from human immortalized oral epithelial cell line. Arch. Oral Biol. 2008; 53; 443–452.
- 27Zhang L, Ye DX, Pan HY et al. Yes-associated protein promotes cell proliferation by activating fos related activator-1 in oral squamous cell carcinoma. Oral Oncol. 2011; 47; 693–697.
- 28Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL, Tumour Angiogenesis Research Group. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway – a report of the Tumour Angiogenesis Research Group. J. Clin. Oncol. 2006; 24; 4301–4308.
- 29Chaika NV, Yu F, Purohit V et al. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLoS One 2012; 7; e32996.
- 30Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization classification of head and neck tumors: pathology and genetics of head and neck tumors. Lyon: IARC Press, 2012.
- 31Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J. Clin. 2005; 55; 242–258.
- 32Cortes-Cros M, Hemmerlin C, Ferretti S et al. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc. Natl Acad. Sci. USA 2013; 110; 489–494.
- 33Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL, Jiang HB. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod. Pathol. 2010; 23; 213–224.
- 34Wei Z, Wang Y, Li Z et al. Overexpression of hippo pathway effector TAZ in tongue squamous cell carcinoma: correlation with clinicopathological features and patients' prognosis. J. Oral Pathol. Med. 2013; 42; 747–754.
- 35Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324; 1029–1033.
- 36Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J. Mol. Med. (Berl.) 2011; 89; 205–212.
- 37Galluzzi L, Kepp O, Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat. Rev. Drug Discov. 2013; 12; 829–846.
- 38Koukourakis MI, Giatromanolaki A, Winter S, Leek R, Sivridis E, Harris AL. Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy. Oncology 2009; 77; 285–292.
- 39Wu S, Le H. Dual roles of PKM2 in cancer metabolism. Acta Biochim. Biophys. Sin. (Shanghai) 2013; 45; 27–35.
- 40Shim H, Dolde C, Lewis BC et al. C-myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl Acad. Sci. USA 1997; 94; 6658–6663.
- 41Yang W, Zheng Y, Xia Y et al. Erk1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 2012; 14; 1295–1304.
- 42Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 2012; 45; 598–609.
Citing Literature
